P
Parabilis Medicines
Biotech & Life Sciences · Cambridge, United States · Founded 2016
Developing helical peptide therapeutics targeting hard-to-drug disease proteins MoreLess
Parabilis Medicines, (formerly know as Fog Pharmaceuticals) is a dynamic startup operating in the pharmaceutical industry, specifically in the field of drug discovery. The company's primary focus is on developing a new class of drugs, known as Helicon therapeutics, to target previously untreatable diseases. Their approach integrates advanced technologies to speed up and scale the process of drug discovery, making it more efficient and effective.
The company's primary market is the healthcare sector, with a particular emphasis on treating cancer. Their lead program, FOG-001, is a first-in-class TCF-blocking β-catenin inhibitor, which is currently undergoing a Phase 1/2 clinical trial. This drug is designed to target the most common yet elusive drivers of cancer, making it a potentially groundbreaking treatment.
FogPharma operates on a business model that combines research, development, and commercialization of pharmaceutical products. They generate revenue through the successful development and sale of these innovative drugs. Additionally, they also likely seek funding from investors who are interested in the pharmaceutical and biotech sector.
The company values learning and collaboration, and is constantly seeking to push the boundaries of science. They are on a mission to shape the future of precision medicine and are looking for passionate individuals to join their team.
In summary, FogPharma is a promising startup that combines cutting-edge technology with innovative science to develop novel treatments for previously untreatable diseases.
Keywords: Drug Discovery, Helicon Therapeutics, Cancer Treatment, Advanced Technologies, Pharmaceutical Industry, Healthcare Sector, Research and Development, Commercialization, Precision Medicine, Innovative Science.
Company overview
Parabilis Medicines company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Employees
- 195
- Open positions
- 19
- Dealroom signal
- 87.5
Valuation & funding
Parabilis Medicines funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VCOther financing | Jun 2026 | $75M | — | Regeneron Pharmaceuticals | ↗ |
| IPOOther financing | Jun 2026 | $670M | $2.4B | Undisclosed | ↗ |
| SERIES FOther financing | Jan 2026 | $305M | $1.2B | GV · Invus · venBio Partners · Nextech Invest | ↗ |
| SERIES EOther financing | Mar 2024 | $145M | $580M | General Catalyst · Farallon Capital Management · Invus · Rock Springs Capital | ↗ |
| SERIES DOther financing | Nov 2022 | $178M | $712M | Fidelity Investments · Invus · ARCH Venture Partners · Deerfield | ↗ |
| SERIES COther financing | Mar 2021 | Farallon Capital Management · Invus · Deerfield · 6 Dimensions Capital | — | ||
| SERIES BOther financing | Jan 2021 | Undisclosed | — | ||
| SERIES BOther financing | May 2018 | WuXi AppTec · Nan Fung Group · 6 Dimensions Capital · Horizons Ventures | — | ||
| EARLY VCOther financing | Jun 2016 | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$142M | — |
| 2025 | $0 | — | −$142M | — |
| 2024 | $0 | — | −$114M | — |
Growth signals
Parabilis Medicines website traffic
Latest recorded traffic for Parabilis Medicines is 17K monthly website visits, up 88.9% over the last three months. Parabilis Medicines's team grew 8.9% over the past year.
Hiring
Open positions at Parabilis Medicines
Current openings linked to this company in Dealroom.
Comparisons
Parabilis Medicines compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Parabilis Medicines's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Parabilis Medicines has talent and traffic
team presence
In the news
Latest news about Parabilis Medicines
Recent press, funding announcements, and product moves mentioning Parabilis Medicines — open to read from the original sources.
Market sentiment
What the market is saying about Parabilis Medicines
An AI-synthesized read of the highest-engagement posts about Parabilis Medicines on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Parabilis Medicines’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.